MedTrace Logo

Seroquel XR in the Long Term Treatment of Schizophrenia

NCT01202617 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1606

Last updated 2011-10-24

No results posted yet for this study

Summary

The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improves the relapse prevention in schizophrenic outpatients

Conditions

  • Relapse in Schizophrenia

Sponsors & Collaborators

Principal Investigators

  • Attila Nemeth · National Psychiatric Centre

  • Lilla Szabo · AstraZeneca

  • Alexandra Henringh · AstraZeneca

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • Hungary

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01202617 on ClinicalTrials.gov